Table 3

Selected outcomes of allo-SCT for relapsed or refractory FL

SeriesReferencePreparative regimenNo. of patientsMRD (%)Prior rituximabNRM (%)NRM timepoint (y)PPFS/EFS (%)PFS timepoint (y)POS (%)OS timepoint (y)P
IBMTR13MA176100NR30545%5515
CIBMTR58MA12010026253673623
RIC8010045285571
EBMT54RIC ATG46100NR183NS553.015703NS
RIC, alemtuzumab42100NR184468
RIC, no TCD76100NR176774
NCCN44Allo-SCT4863100243523613
EBMT53RIC1498062223575675
CIBMTR/EBMT FL1/239RIC26853100265585665
CIBMTR/EBMT FL340RIC6159100275515545
  • ATG, antithymocyte globulin; MA, myeloablative; MRD, matched related donor; NR, not reported; NS, not significant; TCD, T-cell depletion.